ZURA vs. AGEN, OMGA, DBVT, BCAB, CLLS, MOLN, CRDL, OTLK, VIGL, and LIFE
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Agenus (AGEN), Omega Therapeutics (OMGA), DBV Technologies (DBVT), BioAtla (BCAB), Cellectis (CLLS), Molecular Partners (MOLN), Cardiol Therapeutics (CRDL), Outlook Therapeutics (OTLK), Vigil Neuroscience (VIGL), and aTyr Pharma (LIFE). These companies are all part of the "biological products, except diagnostic" industry.
Zura Bio (NASDAQ:ZURA) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking.
61.1% of Zura Bio shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 15.8% of Zura Bio shares are held by company insiders. Comparatively, 4.8% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Zura Bio presently has a consensus price target of $16.40, suggesting a potential upside of 353.04%. Agenus has a consensus price target of $130.00, suggesting a potential upside of 1,803.37%. Given Agenus' higher possible upside, analysts clearly believe Agenus is more favorable than Zura Bio.
Zura Bio has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
In the previous week, Zura Bio had 1 more articles in the media than Agenus. MarketBeat recorded 4 mentions for Zura Bio and 3 mentions for Agenus. Agenus' average media sentiment score of 0.86 beat Zura Bio's score of 0.36 indicating that Agenus is being referred to more favorably in the news media.
Agenus received 454 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 70.05% of users gave Agenus an outperform vote.
Zura Bio has higher earnings, but lower revenue than Agenus.
Zura Bio has a net margin of 0.00% compared to Agenus' net margin of -164.69%. Agenus' return on equity of 0.00% beat Zura Bio's return on equity.
Summary
Zura Bio beats Agenus on 9 of the 16 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
